The global endocrine testing market features a fairly oligopolistic structure with the top five players occupying a combined market share of 90.0% in 2014, finds Transparency Market Research (TMR). These companies are Siemens Healthineers, DiaSorin, Agilent Technologies, Abbott Laboratories, and F. Hoffmann-La Roche AG. Among the leading players, Roche emerged as the dominant players in 2014. The leading companies are developing advanced lab automation systems, next-generation sequencing platforms, endocrine test kits, and analyzers.
Presently, strict competition exists among the key market players and the competitive landscape is expected to intensify further in the coming years. Advancement in product portfolio and developing innovative technologies are the key focus points for players hoping to gain a sustained share in the global endocrine testing market.
The market is anticipated to rise at a CAGR of 8.50% from 2015 to 2023. The opportunities in the global endocrine testing market is projected to rise to US$12.8 bn by the end of 2023.
Asia Pacific to Open up Lucrative Growth Avenues
Based on end user, the endocrine testing market is segmented into hospitals, commercial laboratories, ambulatory care centers, home-based tests, and physician offices. Of these, the commercial laboratories segment is expected to lead the market throughout the forecast period. The extensive demand for endocrine testing in commercial laboratories is propelled by the growing prominence of outsourcing a number of testing procedures.
Geographically, North America is expected to generate the major revenue in the endocrine testing market. The region is projected to lead throughout the forecast period and is anticipated to account for a share of 38.3% by the end of the forecast period. Meanwhile, the Asia Pacific market for endocrine testing is projected to rise at a stellar CAGR during the forecast period and expected to offer a plethora of opportunities for companies.
Advancements in Assays and Diagnostic Methods to Open Up Exciting Opportunities
The rising incidence of diabetes and the growing prevalence of obesity in developing and developed regions are key factors driving the endocrine testing market. The regular monitoring of the hormone endocrine plays a vital role in the management of the disease diabetes in various populations world over. In addition, there is increasing significance of obesity as a co-morbidity factor in the prevalence of cardiovascular diseases, strokes, various cancer types, and various diseases of the reproductive system. This is expected to favorably impact the endocrine testing market across regions.
However, the unaffordability of advanced endocrine testing technologies for a major chunk of population in developing countries is a key factor hindering the growth of the market to an extent. In addition, the limited awareness about healthcare among populations living in low-income regions is likely to impede the global endocrine testing market. Nevertheless, constant advancements in assays and endocrine testing methods are key factors catalyzing the market growth. Furthermore, recent improvements in diagnostic technology such as in liquid chromatography-mass spectrometry (LC-MS) is expected to open up exciting opportunities for market players in the coming years.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Endocrine Testing Market (Test - Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Cortisol Test, Insulin Test Gastrin, Thymosin Secretin; Diagnostic Technology - Tandem Mass spectrometry, Immunoassay Technologies (Enzyme immunoassays and Radioimmunoassays (RIA)), Monoclonal and Polyclonal Antibody Technologies, Sensor Technologies (Electrochemical and Biosensors), Clinical Chemistry Technologies, and Liquid Chromatography-Mass Spectrometry (LC-MS); End User - Hospitals, Commercial Laboratories, Ambulatory Care Centers, Home Based Tests, and Physician Offices) - Global Industry Analysis, Size, Share, Growth Trends and Forecast, 2015 - 2023.”
The global endocrine testing market is segmented based on:
- Estradiol (E2) Test
- Follicle Stimulating Hormone (FSH) Test
- Human Chorionic Gonadotropin (hCG) Test
- Luteinizing Hormone (LH) Test
- Dehydroepiandrosterone sulfate (DHEAS) Test
- Progesterone Test
- Testosterone Test
- Thyroid Stimulating Hormone (TSH) Test
- Prolactin Test
- Cortisol Test
- Insulin Test
- Tandem Mass spectrometry
- Immunoassay Technologies
- Enzyme immunoassays
- Radioimmunoassays (RIA)
- Monoclonal and Polyclonal Antibody Technologies
- Sensor Technologies
- Clinical Chemistry Technologies
- Liquid Chromatography-Mass Spectrometry (LC-MS)
- Commercial Laboratories
- Ambulatory Care Centers
- Home Based Tests
- Physician Offices
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Rest of the World (RoW)
- Middle East and Africa
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453